Introduction
epatic involvement in systemic disorders is common with variable features from fulminant liver failure to cholestatic, hepatocellular or mixed pictures. Thyroid disorders are known to be associated with abnormal liver enzymes 1 . Autoimmune thyroid disorders like hashimoto's thyroditis and Grave's disease may be associated with autoimmune hepatitis as part of multiorgan autoimmune diseases. reatment of hyperthyroidism with oral medication or radioactive iodine I 131 may cause toxic liver injury 2,3,4 . Hyperthyroidism associated cholestasis was reported with both severe and mild hyperthyroidism. This form of cholestasis usually resolves after treatment of hyperthyroidism 5, 6 . This case report is a description of rare association of thyrotoxicosis, cholestasis, and steatosis. J Table 1 . The serum lipids were still the same metformin 500mg twice daily was started as treatment for NAFLD together with thyroxin replacement therapy. The liver enzymes improved to the lowest level since she was diagnosed. After three years of follow up the liver enzymes were still fluctuating but never back to normal pravastatin 10 mg daily was added and she was closely monitored, she had transient improvement of the liver enzyme but once again she had poor compliance to pravastatin. Currently the patient is receiving L thyroxin100 μg/day on the latest outpatient follow up the TSH .085, T429.68, T3 5.92. The liver enzymes showed hepatocellular derangement ALT117, AST90, ALP277 this most likely attributed to obesity associated non alcoholic fatty liver disease.
Discussion
Thyrotoxicosis associated liver enzyme abnormality were reported in up to 37% of thyrotoxic patients 1, 5, 6 The presence of cholestasis in association with thyrotoxicosis is rarely reported 7, 8 . This case represents a rare association of cholestasis and steatosis with thyrotoxicosis. The abnormality of the liver enzymes raises the possibility of autoimmune hepatitis in association with autoimmune thyroid disorders but this was not supported by the finding on the liver biopsy and the IgG level, positive ANA is not specific and could be related to Grave's disease. Primary biliary cirrhosis (PBC) is another autoimmune disease that should be considered in an adult female with autoimmune thyroid disorder presenting with cholestasis, but this was excluded by negative (AMA2) antibody, normal (IgM) level and absence of PBC features on the liver biopsy. Chronic viral hepatitis ( B or C) especially hepatitis C genotype 3 is well known to be associated with steatosis and high GGT level 9, 10 but negative viral markers and the liver biopsy findings were not supportive for the diagnosis of chronic viral hepatitis.
Hepato-toxicity from previous Carbimazole treatment is another possibility but previously reported cases of carbimazole induced cholestasis developed during treatment or shortly after and were associated with clinical jaundice and hyperbilirubinemia 2,3,11 which was not the case in our patient, she had normal bilirubin and on the other hand she stopped taking carbimazole more than one year before she had abnormal liver enzymes. I 131 was reported to cause severe cholestatic hepatitis 4 but in our patient the liver enzymes were abnormal before receiving treatment with I 131 . In a report similar to our patient, Belassoued and colleagues reported a case of thyrotoxic hepatitis and steatosis with favorable outcome after I 131 therapy 12. In the two reported cases by Hull and colleagues the jaundice resolve completely after thyroidectomy 8. Toxic liver injury related to other drugs or herbal medicine was ruled out by history. The patient had normal liver enzymes before the diagnosis of thyrotoxicosis making hyperthyroidism associated cholestasis the more likely cause of her liver abnormalities, but as compared to previously reported cases our patient did not had jaundice or hyperbilrubinemia and she had cholestatic rather than hepatocelluar derangement of liver enzymes. Another form of thyrotoxicosis associated cholestasis was reported in association with thyroid storm. 8, 13 .
The patient did not have family history of hyperlipidemia but her base line serum cholesterol was high. In spite of low fat diet trials and pravastatin she maintained the same level of serum cholesterol during the follow up but the liver enzymes significantly improved after I 131. therapy. Non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) usually present's with hepatocellular liver enzymes abnormalities (elevated ALT and AST) 14 but NAFLD can sometimes present with cholestasis 15 but ALP and GGT are poor markers for NASH. 14 NAFLD and NASH are likely to be associated with hypothyrodism because of weight gain and hyperlipidemia this may explain the deterioration in the liver enzymes after initial improvement with the evolution from hyperthyroidism to hypothyrodism after I 131 therapy. The learning lesson from this case and from the reviewed literature that liver enzymes abnormality are commonly associated with thyrotoxicosis reassessment of the liver enzymes after achievement of euothyroid status is important to differentiate thyroid associated hepatic derangements from other liver diseases. To conclude, our patient had thyroaoxicosis associated cholestasis and steatosis with high body mass index, she had significant improvement of the liver enzymes after the treatment of thyrotoxicosis. The pattern of hepatic dysfunction changed from cholestatic to hepatocellular picture. Thyrotoxicosis associated cholestasis is a rare disorder with good response to the treatment of thyrotoxicosis. Its pathogenesis and the immunological back grounds are not clear. More data may be needed to understand thyroid associated liver abnormalities.
